Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBITDA: 2017-2024

Historic EBITDA for Tonix Pharmaceuticals Holding (TNXP) over the last 8 years, with Dec 2024 value amounting to -$136.7 million.

  • Tonix Pharmaceuticals Holding's EBITDA fell 112.59% to -$33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year increase of 29.43%. This contributed to the annual value of -$136.7 million for FY2024, which is 15.48% down from last year.
  • Tonix Pharmaceuticals Holding's EBITDA amounted to -$136.7 million in FY2024, which was down 15.48% from -$118.4 million recorded in FY2023.
  • Tonix Pharmaceuticals Holding's 5-year EBITDA high stood at -$50.5 million for FY2020, and its period low was -$136.7 million during FY2024.
  • In the last 3 years, Tonix Pharmaceuticals Holding's EBITDA had a median value of -$118.4 million in 2023 and averaged -$122.4 million.
  • Data for Tonix Pharmaceuticals Holding's EBITDA shows a maximum YoY slumped of 82.76% (in 2021) over the last 5 years.
  • Tonix Pharmaceuticals Holding's EBITDA (Yearly) stood at -$50.5 million in 2020, then slumped by 82.76% to -$92.3 million in 2021, then dropped by 21.43% to -$112.1 million in 2022, then declined by 5.61% to -$118.4 million in 2023, then declined by 15.48% to -$136.7 million in 2024.